Related Experiment Video
Updated: Mar 30, 2026

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
Published on: January 19, 2024
Engineering strategies for the clinical translation of organoids
Lipeng Liao1, Yuan Meng2, Yuhang Shi1
1Department of Spine Surgery, Peking University Shenzhen Hospital, PKU-Shenzhen Clinical Institute of Shantou University Medical College, Shenzhen 518036, China; Shenzhen Key Laboratory of Spine Surgery, Department of Spine Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Background:
Organoids are moving from self-organized three-dimensional (3D) cultures toward engineered living systems with translational intent. Yet most platforms still rely on static, poorly defined matrices and limited control over architecture, maturation, and batch reproducibility. Clinical translation exposes scale dependent constraints AIM OF REVIEW: This review reframes organoid translation as an engineering continuum that links controllable variables across three stages: in vitro microenvironment engineering, engineering enabled in vitro translational workflows, and in vivo clinical translation.
Key Scientific Concepts Of Review:
We summarize how engineered microenvironments provide quantitative control over stiffness, geometry, and transport to improve reproducibility during organoid construction. We then discuss engineering enabled workflows that introduce dynamic conditioning and functional benchmarking to bridge in vitro performance with translational requirements. For in vivo application, we highlight vascularization and immune compatibility as a coupled bottleneck and define functional integration as measurable system level contribution rather than structural persistence alone. Together, these strategies outline a scale aware and clinically aligned engineering framework for organoid translation.

